Oncology NEWS International Vol 19 No 8

Who's News

August 10, 2010

A Seattle cancer center appoints a new leader while ASCO bestows development awards on international researchers. Learn more about the latest appointments and accolades in the cancer community.

Sonography better to monitor small testicular lesions

August 10, 2010

There is a lack of scientific evidence about the risk of testicular cancer associated with testicular lesions, but the conventional treatment approach has been immediate surgical removal because of the possibility of malignancy. A more conservative approach has served one Canadian institution well when it comes to active surveillance of small, incidentally discovered testicular masses.

Cell-signaling pathway may be new Rx target ER+ breast cancer

August 10, 2010

Cancer investigators at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., have confirmed that the PI3-kinase (PI3K) pathway offers a promising therapeutic target in patients who develop resistance to standard endrocine therapies.

Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML

August 10, 2010

Imatinib (Gleevec), the first-line standard of care in chronic myeloid leukemia, will become a generic drug in 2015, so the race is on to find a second generation of tyrosine kinase inhibitors (TKIs) that can do the job just as well.

From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time

August 10, 2010

Eighteen-month follow up supports lower-dose nilotinib as the new standard of care for newly diagnosed chronic myeloid leukemia. The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+CML Patients) enrolled 846 patients at 217 sites in 35 countries. Timothy P. Hughes, MD, MBBS, will present an update to the ENESTnd trial at ASH 2010.